Will Atreca, Inc. (BCEL) Go Down Anytime Soon?

The stock of Atreca, Inc. (NASDAQ:BCEL) is a huge mover today! The stock increased 19.97% or $2.68 during the last trading session, reaching $16.1. About 75,341 shares traded. Atreca, Inc. (NASDAQ:BCEL) has 0.00% since August 15, 2018 and is . It has by 0.00% the S&P500.
The move comes after 9 months positive chart setup for the $449.96M company. It was reported on Aug, 15 by Barchart.com. We have $17.55 PT which if reached, will make NASDAQ:BCEL worth $40.50M more.

More notable recent Atreca, Inc. (NASDAQ:BCEL) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: Sanofi’s Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering – Benzinga” on August 06, 2019, also Benzinga.com with their article: “Atreca IPO: What You Need To Know – Benzinga” published on June 19, 2019, Benzinga.com published: “75 Stocks Moving In Friday’s Mid-Day Session – Benzinga” on August 09, 2019. More interesting news about Atreca, Inc. (NASDAQ:BCEL) were released by: Benzinga.com and their article: “76 Biggest Movers From Yesterday – Benzinga” published on August 13, 2019 as well as Nasdaq.com‘s news article titled: “Solid tumor biotech Atreca files for a $100 million IPO – Nasdaq” with publication date: May 24, 2019.

Atreca, Inc., a biopharmaceutical company, discovers and develops antibody immunotherapeutics to treat a range of solid tumor types. The company has market cap of $449.96 million. The Company’s lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. It currently has negative earnings. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.